Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolus reports robust Q4 earnings, eyes international expansion and profitability

Evolus' Q4 2022 performance exceeded expectations, driven by strong revenue growth and customer acquisition.
The company's strategic focus on market share gains, international expansion, and profitability sets a positive trajectory.
Challenges from new competition and market dynamics require strategic responses to maintain leadership.
Opportunities in international expansion, corporate development, and market growth position Evolus for future success.

Evolus secures strategic partnership for growth in dermal filler market

Evolus' strong Q1 performance and strategic partnership with Symatese position the company for significant growth in the dermal filler market.
While facing challenges in safety comparisons and patient demographics, Evolus has opportunities to leverage its unique manufacturing process and upcoming data releases for market advantage.
Overall, Evolus is well-funded, poised for profitability, and focused on differentiating its product line for long-term success.

Evolus (EOLS) exceeds Q2 sales targets, eyes international expansion

Evolus (EOLS) delivered a strong performance in Q2, with accelerated sales growth, efficient cost management, and a focus on profitability, positioning the company for future success.
While facing challenges in market penetration and profitability, Evolus's strategic strengths in customer acquisition, innovation, and financial discipline provide a solid foundation for growth.
With opportunities for revenue expansion, international market growth, and disruptive product launches, Evolus is poised to capitalize on its strengths and address key challenges to drive long-term value for investors.

Evolus (EOLS) achieves record revenue and profitability, eyes global expansion

Evolus (EOLS) delivered a stellar performance in Q3 2023, with record revenue, strong financials, and promising R&D outcomes, positioning the company for continued growth and profitability.
The company's strategic strengths lie in market expansion, brand loyalty, and a clear long-term vision, supported by confidence in achieving ambitious revenue targets and product innovation.
While challenges in market competition and resource optimization persist, Evolus has opportunities in market segments, international expansion, and industry visibility to drive future growth.

Evolus surpasses revenue targets, eyes $700 million goal by 2028

Evolus delivered strong financial performance in Q4 2023, exceeding revenue expectations and achieving profitability. With a strategic focus on market expansion, product differentiation, and customer engagement, the company aims to reach a revenue target of $700 million by 2028.

Evolus reports robust Q1 growth, eyes $700M revenue target by 2028

Evolus demonstrated strong financial performance and market expansion in Q1 2024, with a focus on operational efficiency and customer engagement. The company's strategic goals include achieving profitability by year-end and targeting substantial revenue growth by 2028.
While facing challenges in market dynamics and profitability targets, Evolus remains optimistic about its competitive position and growth prospects. Opportunities lie in leveraging loyalty programs, expanding internationally, and launching new product lines to drive future success.

Evolus reports profitable Q2, eyes global expansion and new products

Evolus demonstrated strong performance in Q2 2024, achieving profitability and revenue growth.
The company's focus on innovation, international expansion, and financial management positions it for future success.
Challenges lie in maintaining growth momentum, executing expansion plans, and managing costs effectively.
Opportunities include capitalizing on market demand, global expansion, product innovation, and financial optimization.

Evolus reports strong Q3 growth, eyes $700M revenue target

Evolus showcased robust growth and strategic initiatives in Q3 2024, aiming for significant revenue targets by 2028. While facing revenue challenges and market competition, the company's strengths in product innovation and market expansion offer opportunities for sustained growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evolus, Inc. (EOLS) Q3 2023 Earnings Call Transcript

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2023. “The record results of our third quarter reflect the continued strength in sales and consistent execution of our long-term growth strategy,” said David Moatazedi, President and Chief Executive Officer. “Notably, we achieved record quarterly revenue of.

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced results from the Phase 2 clinical study evaluating the “extra-strength” 40U dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), the only neurotoxin dedicated exclusively to aesthetics. Final data were presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, i.

“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will present at the following investment conferences in November.   Event:   Stifel 2023 Healthcare Conference   Date:   Wednesday, November 15, 2023   Time:   11:30 AM ET           Event:   6th Annual Evercore ISI HealthCONx Conference   Date:   Tuesday, November 28, 2023   Time:.

Evolus to Participate in November Investor Conferences

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will fo.

Evolus to Report Third Quarter 2023 Results

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sue Ellen Cox M.D. will present final results from the Phase 2 study evaluating the safety, efficacy and duration of effect of 40U PrabotulinumtoxinA-xvfs at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting on November 3, 2023, in Chicago during an independent medical education session.

Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting

Coeur Mining

VAALCO Energy

Geron

Nerdy

Planet Labs

Taboola

While targeting small-cap stocks to buy might not be the go-to recipe for predictable and consistent market success, in some cases, you just have to do what you have to do. Think of it this way.

7 Must-Own Small-Cap Stocks That Could Outperform the Market

Evolus, Inc. provides medical aesthetic products and competes against Botox with its main product, Jeuveau. The company is gaining market share and continues to add members to its core loyalty program. Evolus is expected to deliver 30% annual revenue growth in the coming years, and losses should continue to narrow with profitability in sight for 2025.

Evolus: Gaining Market Share

Clean Energy Fuels

DocGo

Freyr Battery Inc

NaaS Technology Inc

NerdWallet

SoundHound AI Inc

To be quite blunt, small-cap stocks to buy are like the chimpanzees of the equities space. While you may mistake a chimp for being weak due to its relatively short stature, that would be a mistake.

7 Small-Cap Stocks Analysts Predict Will Double in 2024

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in two investment conferences in September. Event: H.C. Wainwright 25th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Time: 11:00 – 11:30 am ET Event: Cantor 2023 Global Healthcare Conference Date: Tuesday, September 26, 2023 Time: 9:1.

Evolus to Participate in September Conferences

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 83,555 shares of Evolus common stock and 63,358 restricted stock units (RSUs) to Tomoko Yamagishi-Dressler, the company's new Chief Marketing Officer. The stock options and RSUs were granted as o.

Evolus Announces Inducement Grants for New Chief Marketing Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today.

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus unveils fresh, new branding for its flagship neurotoxin product, Jeuveau.

Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers

Evolus, Inc. (NASDAQ:EOLS ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Navann Ty - BNP Louise Chen - Cantor Fitzgerald Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Greetings and welcome to the Evolus Second Quarter 2023 Earnings Conference Call.

Evolus, Inc. (EOLS) Q2 2023 Earnings Call Transcript

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Evolus Reports Second Quarter 2023 Results and Provides Business Update

The company increased full-year revenue guidance to between $185 million and $195 million. Second-quarter revenue was up 33% year over year.

Why Shares of Evolus Are Jumping Thursday

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus reported revenue for the second quarter ended June 30, 2023 and raised its revenue guidance for the full year.

Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus announced that members of its management team will be participating in Canaccord Genuity's 43rd Annual Growth Conference in Boston.

Evolus to Participate in Canaccord Genuity's 43rd Annual Growth Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus announced that it will report its second quarter 2023 financial results and provide a business update on Wednesday, August 2, 2023.

Evolus to Report Second Quarter 2023 Results and Provide Business Update

Evolus, Inc., a pharmaceutical company specializing in aesthetic products, faces significant challenges with its lead product Jeuveau, a treatment for frown lines. Jeuveau's undifferentiated clinical data compared to established competitor Botox, aggressive pricing strategies in the market, and the entry of long-acting neurotoxins like Daxxify from Revance make its launch and market penetration difficult. The company's financial position is precarious, with only $31m cash on hand and a quarterly cash burn rate of $15m. The company's value is heavily reliant on Jeuveau, making it vulnerable to market shifts and changes in consumer preference.

Evolus: Botox Copy Cat In A Challenging Aesthetic Market

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. has commenced the commercial launch of Nuceiva® in Italy. The product is now available for direct order and delivery to customers.

Evolus Launches Nuceiva® (botulinum toxin type A) in Italy

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. announced the completion of its Phase 2 clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau®.

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. announced it recently completed the one-millionth Jeuveau® redemption through its Evolus Rewards™ patient loyalty program.

Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program

Evolus, Inc. (NASDAQ:EOLS ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Marc Goodman - SVB Securities Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Evolus First Quarter 2023 Earnings Conference Call.

Evolus, Inc. (EOLS) Q1 2023 Earnings Call Transcript

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc. reports financial results for the first quarter ended March 31, 2023 and provides a business update.

News for Evolus Stock (EOLS)